Purpose: It remains unclear whether eosinophilia is useful for in guiding inhaled corticosteroid (ICS) therapy in chronic obstructive pulmonary disease (COPD) patients.
central role in the pathophysiology of COPD as they are related to lung function decline, poor health status, and increased mortality. 3 While nonresponse to ICS therapy is common, 4 potential side effects of ICS include fractures and pneumonia.
Clinical data have suggested that blood eosinophil count, which is present in up to 40% of COPD patients, 5 is a promising biomarker of response to ICS in patients with COPD. [6] [7] [8] [9] Eosinophilic airway inflammation has been associated with an increased risk of exacerbations, and patients with eosinophilic inflammation responded better to ICS therapy than noneosinophilic patients. 6 , 10 Pascoe and colleagues 6 performed a post hoc analysis of data from 2 replicate, randomised, double-blind trials with duration of 12 months. In the analysis, vilanterol 25 μg was compared with 25 μg vilanterol plus 50, 100, or 200 μg fluticasone furoate in patients with moderate-to-severe COPD. They observed that 68% of COPD patients had peripheral blood eosinophilia. Importantly, across all doses of ICS, fluticasone furoate and vilanterol reduced exacerbations by 29% compared with vilanterol alone in patients with eosinophil counts ≥2%, and by 10% in patients with eosinophil counts <2%. Analysis of data from the FLAME trial showed no significant reduction in exacerbation in indacaterol/ gycopyrronium compared to salmeterol/fluticasone among patients with blood eosinophil levels of 150 to 300 cells/μL versus 300 cells/ μL. 8 In this study, we use the word "eosinophilia" to mean an elevated blood eosinophil count based on our defined cutoffs.
However, studies with real-world evidence are currently limited and are needed to identify patients who will benefit from ICS use.
Therefore, the aim of this study was to evaluate the risk of acute exacerbations, COPD-related hospitalisations/accident and emergency visits, and all-cause mortality, with various levels of eosinophil counts among COPD patients using ICS.
2 | METHODS
| Data source
This study was conducted with data obtained from the Clinical Prac- to study COPD. [15] [16] [17] The independent scientific advisory committee of MHRA database research approved the study protocol (17_065R).
| Study population
We selected all patients aged ≥40 years with a diagnosis of COPD, as recorded by a first read code during valid data collection from January 
KEY POINTS
• We found no reduced risk of COPD-related acute exacerbations or hospitalizations/A&E visits among patients with blood eosinophilia using ICS.
• However, all-cause mortality was reduced among current ICS users with blood eosinophilia compared to current ICS users with low relative blood eosinophil count.
• The findings have important implications on targeted prescribing of Inhaled corticosteroids among COPD patients based on blood eosinophil counts in general practice.
this analysis approach because of its reliability in adequately assess exposure status and covariates essential to the validity of our results. 21 
| Covariates
Potential confounders were assessed time-dependently; with the exception of gender, smoking status, alcohol use, and body mass index, which were determined at baseline. The following confounders were considered as potential confounders, and identified at the start of each 90-day interval: a history of congestive heart failure, anaemia, chronic liver disease, allergic rhinitis, all malignancies except nonmelanoma skin cancer, ischaemic heart disease, stroke, rheumatoid arthritis, diabetes mellitus, hypertension, pulmonary fibrosis, osteoporosis, and anxiety. Additionally, the use of antihistamines, oxygen, proton-pump inhibitors, antipsychotics, antidepressants, or statins was identified in the past 6 months. [22] [23] [24] [25] [26] We adjusted for proxy indicators of the severity of obstructive airway disease, as previously defined as dispensed prescriptions of short and long-acting beta-agonists, short and long acting muscarinic antagonists, xanthine derivatives, and oral corticosteroids.
27,28
| Statistical analysis
We evaluated the risk of study outcomes stratified by ICS use, gender, and age using Cox regression analysis (SAS 9.4 PHREG procedure). Current ICS use was further stratified by blood eosinophil counts. The difference between each eosinophil count strata was tested using Wald's test for relative and absolute blood eosinophil counts. To avoid immortal time bias, all patients were classified as never users until the first ICS prescription after the index date, and all exposure categories of ICS use were incorporated into the statistical model time-dependently. We ran FIGURE 1 Flow chart showing the selection of eligible patients Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body mass index; SABAs, short-acting beta-2 agonists; LABAs, long-acting beta-2 agonists; SAMAs, short-acting muscarinic antagonists; LAMAs, long-acting muscarinic antagonists; ICS, inhaled corticosteroids.
separate models for age, gender, and absolute and relative counts avoiding collinearity between absolute and relative eosinophil counts.
Potential confounders were included in the final models if they independently changed the β-coefficient for current ICS exposure by at least 5%, or when consensus existed within the team of researchers.
| RESULTS
We identified 213 561 patients with COPD, of whom 32 693 met the inclusion criteria (Figure 1 ). Table 1 shows the baseline characteristics of COPD patients, which were predominantly elderly males. At baseline, the mean blood eosinophil count was 3.1% (±2.7%), and 64.1%
had a relative blood eosinophil count ≥2.0%. More than half of all patients were either overweight (31.9%) or obese (25.8%), and a considerable proportion of COPD patients suffered from ischemic heart disease (15.4%). We evaluated the risk of study outcomes stratified by ICS use, gender, and age using Cox regression analysis.
| Acute COPD exacerbations
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years.
a Adjusted for age, gender, smoking status, alcohol use, BMI, a history of heart failure, diabetes mellitus, chronic liver disease, pulmonary fibrosis, ischaemic heart disease, osteoporosis, anxiety, hypertension, anaemia, and the use of antipsychotics, statins, oxygen, proton-pump inhibitors, antidepressants, or antipsychotics, long-acting beta-2 agonist, short-acting beta-2 agonist, short-acting muscarinic agent, long-acting muscarinic antagonist, xanthine derivatives, and oral corticosteroid use 6 months prior to the start of an interval.
b Adjusted for all confounders under (a) except gender. 
| DISCUSSION
We found no reduced risk of COPD-related acute exacerbations or hospitalisations/AE visits among patients with blood eosinophilia among COPD patients using ICS. However, all-cause mortality was reduced among current ICS users with blood eosinophilia compared to current ICS users with low relative blood eosinophil count. However, this effect could not be detected with absolute eosinophil counts.
| ICS use and risk of exacerbations or COPDrelated hospitalisations/AE visits
As compared to never users, current users of ICS had a significantly increased risk of exacerbations or COPD-related hospitalisations/AE visits, although the risk between recent and current users was comparable. Similarly, Melo et al found an increased risk of first exacerbation among COPD patients currently exposed to ICS. 27 Since ICS are prescribed in order to prevent these events, confounding by disease severity may explain this, in particular because the association is also present among ICS users who have recently stopped taking the drugs (recent users). Furthermore, recent and current users of ICS in our study might represent a different phenotype of COPD patients, maybe the so-called frequent exacerbators. 29 Although, a multicentre 4-year double blind study in COPD patients also reported an increased risk of first COPD exacerbation in patients exposed to any ICS compared to patients not exposed to ICS. exacerbations compared to those with low blood eosinophil counts.
While our observational study results are in contrast to this, it is important to note that we excluded patients with a history of asthma while Pascoe and coworkers excluded only active asthma patients and included patients with a history of one or more exacerbations in the previous year. 33 The FLAME trial evaluated the time to the first exacerbation in COPD patients exposed to indacaterol/gycopyrronium compared to salmeterol/fluticasone and found no significant risk reduction in exacerbation among patients with blood eosinophil levels of 150 up to 300 cells/μL, versus 300 cells/μL or more. 8 When comparing our results to both previous studies, an important distinction was the comparator group, which may explain differences in results.
Our findings were consistent with post hoc analyses from the ISOLDE trial. 34 It showed no difference in the time-to-first exacerbation in patients with high or low eosinophil counts. It is important to note that our study also employed the time-to-first exacerbation approach. Similar to our study, 3 randomised clinical trials that studied blood eosinophils and ICS/long acting bronchodilator reported no statistically significant effects for time to first moderate/severe exacerbation in patients with relative eosinophils counts ≥2% versus counts <2%. 35 
| Impact of blood eosinophil counts on all-cause mortality
Our findings are in agreement with a study which evaluated the 3-year survival using relative eosinophil count cutoff of ≥2%, which showed that COPD patients with higher blood eosinophil counts had a significantly decreased 3-year mortality compared to COPD patients with blood eosinophil counts <2% exposed to ICS. 36 However a randomised, double-blind, placebo-controlled study by Barnes and coworkers 34 using subjects from the ISOLDE study found no difference in the risk of deaths in COPD patients exposed to ICS with different eosinophil counts. Similarly, a clinical study involving 303 patients with COPD found that elevated blood eosinophil counts (≥200, 300, 400 cells/μL) were not associated with mortality when compared with patients with decreased eosinophil counts. 37 In recent years, various researchers have questioned the use of the 2% cutoff adopted by various studies to determine effective response to ICS in patients with COPD; others have argued in favour of the use of absolute blood eosinophil counts in making clinically beneficial decisions for patients with COPD. 5, 38, 39 As absolute counts are We evaluated the risk of hospitalisation/AE visits for COPD stratified by ICS use, gender, and age using Cox regression analysis.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years; AE, accident and emergency.
a Adjusted for age, gender, smoking status, alcohol use, BMI, a history of heart failure, diabetes mellitus, chronic liver disease, pulmonary fibrosis, ischaemic heart disease, osteoporosis, anxiety, hypertension, anaemia, and the use of antipsychotics, statins, oxygen, proton-pump inhibitors, antidepressants, antipsychotics, long-acting beta-2 agonist, short-acting beta-2 agonist, short-acting muscarinic agent, long-acting muscarinic antagonist, xanthine derivatives, and oral corticosteroid use 6 months prior to the start of an interval.
b Adjusted for all confounders under (a) except gender. less affected by total white blood cell count, 8 Vedel-Krogh et al suggested that 0.34 × 10 9 cells/L cutoff was appropriate in detecting COPD exacerbations because this cutoff was associated with increased risk of moderate and severe exacerbations in patients with COPD in population-based settings. 5 The exact mechanism underlying the presumed changes in COPD-related exacerbation in patients with varying baseline blood eosinophil counts remains unclear. 6, 7 However, it might be due to the non-T helper 2 eosinophilic inflammation in COPD, induced by the epithelial innate lymphoid cell type 2 pathways.
Innate lymphoid cell type 2 has been recognised in relation to the pathogenesis in severe nonallergic eosinophilic asthma. 40 
| Strengths and limitations
A major strength to this study was the use of data from one of the world's largest primary care databases, thereby providing a very large population-based cohort of COPD patients with eosinophil measurements. Second, we used a validated definition for an acute exacerbation of COPD, using read codes which were reported to show a 96%
PPV of identifying an acute exacerbation within the CPRD. 18 Nevertheless, we may have missed a considerable amount of exacerbations that may be miscoded, eg, as respiratory tract infections or pneumonia. Third, classification of exposure to ICS and covariates timedependently during follow-up allowed us to conduct an "on treatment analysis," which results in less nondifferential misclassification of exposure than in an "intention to treat analysis" which ignores ICS exposure during follow-up. Fourth, we eliminated patients with a history of asthma to avoid patients with reversible airflow limitation from our study. Lastly, we had information on important confounding factors such as smoking status, BMI, and other comorbidities and drug use.
Despite numerous strengths, this study also had limitations. In addition to those already mentioned, there is a potential for residual confounding as we lacked information on the disease severity and previous exacerbations. Although the positive predictive value of identifying patients with COPD in the CPRD is 90%, 11 lung function data were unavailable. While we excluded asthma patients, it was impossible to rule out the inclusion of patients with reversible airflow limitation. 41 We lacked information on cause-specific mortality; as such, we could not perform detailed analysis on the cause of death.
Eosinophil counts are not been routinely collected as part of diagnosis of COPD patients, and thus, the patient population in this study may not be representative of all COPD patients. Moreover, this could have masked a true association between eosinophil counts and various outcomes. Inhaled corticosteroid inhalers are known to last for 25 to 100 days depending on the active ingredient and the dose Adjusted for age, gender, smoking status, alcohol use, BMI, heart failure, atrial fibrillation, diabetes, anxiety, chronic liver disease, all cancers except nonmelanoma skin cancer, stroke, antipsychotics, long-acting beta-2 agonist, short-acting beta-2 agonist, short-acting muscarinic agent, long-acting muscarinic antagonist, xanthine derivatives and oral corticosteroid use 6 months prior to the start of an interval.
b Adjusted for all confounders under (a) except gender. prescribed by the GP 42 ; this might have led to a nondifferential misclassification of ICS exposure, masking the true effect (bias towards the null) leading to insignificant findings. Without this potential distortion, the risk of acute exacerbations or hospitalisation/AE visits might have been lower for patients with elevated blood eosinophil counts. However, we detected a significant risk of all-cause mortality irrespective of blood eosinophil counts; we do not believe that our results are influenced by the potential of a nondifferential misclassification.
In conclusion, among COPD patients, we did not find a reduced risk of COPD-related acute exacerbations or hospitalisations/AE visits among patients with blood eosinophilia in COPD patients using ICS.
However, all-cause mortality was reduced among current ICS users with blood eosinophilia compared to current ICS users with low relative blood eosinophil count. However, this effect could not be detected with the absolute eosinophil counts. There is an increasing body of evidence linking blood eosinophil counts to clinically relevant outcomes in patients with COPD. As such, these findings are potentially important and require further evaluation in prospective studies.
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